ACRO Biomedical Co., Ltd.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
ACRO Biomedical was founded in June 2014 and positioned to develop biomaterials for human tissue engineering and regenerative medicine. ACRO uses its proprietary supercritical CO₂ extraction technology to remove cells, fat, and non-collagenous proteins from animal tissues and organs while leaving the intact collagen scaffolds as the biomaterial for high-end medical devices in the field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, etc.
Besides from the development of native scaffolds, ACRO has advanced in combining these tissue scaffolds with stem cells and/or somatic cells for human cell therapy in the field of skin regeneration and knee joint cartilage regeneration.
The ultimate goal for ACRO is whole organ engineering for heart, liver, and kidney transplantation. We wish to recellularize the organ scaffold in vivo for autologous organ transplantation by grafting the decellularized natural organ scaffolds back into the live animal or human body.
Ticker:
6748
Exchange:
Taipei Exchange
Company Type:
Company HQ State:
Not Provided
Company HQ Country:
Taiwan
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Collagen Ophthalmic Matrix
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
ACRO Biomedical Co., Ltd.